The offering will dilute existing shareholders by ~17-20%, likely pressuring the stock near term. Monitor for potential additional dilution if underwriters exercise the greenshoe option. The increased cash runway supports ongoing clinical programs (RGX-202, ABBV-RGX-314, NAVSUNLI) but does not change the fundamental risk profile.
Price Chart
Executive Summary
REGENXBIO priced a $100M underwritten public offering of 10M shares at $9.00/share plus 1.1M pre-funded warrants, representing ~17-20% dilution of existing shares. The offering closes July 20, with underwriters holding a 30-day option for an additional 1.67M shares. This capital raise provides cash runway but significantly dilutes current holders.
Key Financial Metrics
Key Facts
- Gross proceeds of ~$100M from 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999/warrant
- Underwriters have 30-day option to purchase an additional 1,667,250 shares
- Offering expected to close July 20, 2026
- Joint book-runners: Morgan Stanley, J.P. Morgan, Leerink Partners, Mizuho
- Dilution of ~17-20% based on market cap of $579M at $9.00/share
Financial Impact
$100M gross proceeds with ~17-20% dilution of outstanding shares
Risk Factors
- Further dilution if underwriters exercise the 30-day option for 1.67M additional shares
- Stock price may decline as new shares enter the market and existing holders absorb dilution
- No specific use of proceeds disclosed, raising uncertainty about capital allocation efficiency
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302828273 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access